Amundi Pioneer Asset Management Inc. Decreases Holdings in GlaxoSmithKline plc (GSK)

Amundi Pioneer Asset Management Inc. trimmed its holdings in GlaxoSmithKline plc (NYSE:GSK) by 0.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,781 shares of the pharmaceutical company’s stock after selling 2,540 shares during the quarter. Amundi Pioneer Asset Management Inc.’s holdings in GlaxoSmithKline were worth $18,980,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Keystone Financial Planning Inc. lifted its stake in GlaxoSmithKline by 1.1% in the 1st quarter. Keystone Financial Planning Inc. now owns 130,520 shares of the pharmaceutical company’s stock worth $5,099,000 after purchasing an additional 1,418 shares in the last quarter. FTB Advisors Inc. lifted its stake in GlaxoSmithKline by 38.6% in the 1st quarter. FTB Advisors Inc. now owns 5,180 shares of the pharmaceutical company’s stock worth $209,000 after purchasing an additional 1,443 shares in the last quarter. Grove Bank & Trust lifted its stake in GlaxoSmithKline by 6.0% in the 1st quarter. Grove Bank & Trust now owns 26,534 shares of the pharmaceutical company’s stock worth $1,037,000 after purchasing an additional 1,512 shares in the last quarter. Profund Advisors LLC lifted its stake in GlaxoSmithKline by 3.0% in the 4th quarter. Profund Advisors LLC now owns 52,264 shares of the pharmaceutical company’s stock worth $1,854,000 after purchasing an additional 1,519 shares in the last quarter. Finally, Providence Capital Advisors LLC lifted its stake in GlaxoSmithKline by 8.0% in the 1st quarter. Providence Capital Advisors LLC now owns 21,491 shares of the pharmaceutical company’s stock worth $840,000 after purchasing an additional 1,592 shares in the last quarter. 11.07% of the stock is currently owned by institutional investors and hedge funds.

GlaxoSmithKline opened at $40.89 on Friday, MarketBeat.com reports. GlaxoSmithKline plc has a fifty-two week low of $34.52 and a fifty-two week high of $44.44. The company has a debt-to-equity ratio of 3.90, a current ratio of 0.61 and a quick ratio of 0.40. The company has a market capitalization of $101.73 billion, a P/E ratio of 14.20, a P/E/G ratio of 2.31 and a beta of 0.83.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by ($0.02). GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $10.26 billion. sell-side analysts expect that GlaxoSmithKline plc will post 2.84 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 12th. Investors of record on Friday, May 11th will be issued a $0.5298 dividend. The ex-dividend date is Thursday, May 10th. This represents a $2.12 annualized dividend and a yield of 5.18%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 72.92%.

Several analysts have recently commented on GSK shares. Zacks Investment Research lowered shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Thursday, June 14th. DZ Bank reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, June 14th. ValuEngine lowered shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Friday, May 4th. Finally, Deutsche Bank reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, March 28th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $40.21.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply